Condition (MeSH)
von Willebrand Disease, Type 1
ClinicalTrials.gov lists 2 trials for von Willebrand Disease, Type 1 or a narrower condition beneath it. Five Liters, Inc. has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
2 of the 2 trials are tagged with von Willebrand Disease, Type 1 itself; the rest are tagged with a narrower condition beneath it.
When did von Willebrand Disease, Type 1 trials start? (2)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2023 | 1 |
| 2019 | 1 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 2 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are von Willebrand Disease, Type 1 trials in? (2)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Not applicable | 1 |
| Observational | 1 |
How many von Willebrand Disease, Type 1 trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 1 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most von Willebrand Disease, Type 1 trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Five Liters, Inc. | 1 |
Which publications cover von Willebrand Disease, Type 1? (8)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Impact of tranexamic acid on postpartum hemorrhage in type 1 von Willebrand disease treated with recombinant VWF. | Blood advances | 2025 | Yes |
| Longitudinal bleeding assessment in von Willebrand disease utilizing an interim bleeding score. | Journal of thrombosis and haemostasis : JTH | 2022 | Yes |
| Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States. | Blood | 2016 | Yes |
| Prophylaxis in von Willebrand Disease: Coming of Age? | Seminars in thrombosis and hemostasis | 2016 | Yes |
| VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. | Blood | 2013 | Yes |
Showing 5 of 8 publications.
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Von Willebrand disease type 1 | Point prevalence | 1-5 / 10 000 | Europe | Not stated | Exact |
| Von Willebrand disease type 1 | Point prevalence | 1-5 / 10 000 | Europe | Not stated | Exact |
| Von Willebrand disease type 1 | Point prevalence | 1-5 / 10 000 | Europe | Not stated | Unspecified |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Von Willebrand disease type 1 | 166078 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Von Willebrand disease type 1 | 166078 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.